Low-quality Tumor Biopsies

Several specimen features can undermine interpretation at the same time. Too few viable tumor cells may limit what can be concluded, while extensive necrosis reduces usable tissue. Crush and fixation artifacts can obscure histologic detail, and tissue from a nonrepresentative area may fail to reflect the lesion. These problems can therefore affect both diagnosis and characterization.

Biomarker and molecular testing depend on having suitable tumor material, so inadequate specimens may not support reliable assessment. A sample with limited viable tumor or substantial necrosis can restrict the material available for these analyses. When results cannot be interpreted confidently, clinicians may need additional tissue or another sample before using findings to guide treatment selection.

Artifacts arise from specimen handling or preservation, whereas an unrepresentative sample reflects what was collected from the lesion. Crush or fixation artifacts can interfere with histologic interpretation even when tissue was taken from the intended site. Conversely, well-preserved tissue may still provide misleadingly limited information if it does not reflect the lesion’s relevant features.

Pathologists and clinical teams assess specimen adequacy before relying on the results. Their review considers whether the tissue contains enough usable tumor and whether preservation or sampling limitations could affect interpretation and testing. If adequacy is uncertain, the team can integrate imaging findings, consider a repeat biopsy, or evaluate an alternative sample rather than treating a limited result as definitive.

Improving collection, handling, and processing can reduce nondiagnostic results by preserving material that supports interpretation and downstream testing. The goal is not simply to obtain tissue, but to maintain its usefulness for histology and molecular or biomarker assessment. Better specimen quality can reduce the need for additional sampling and help prevent avoidable delays in patient care.

Additional sampling becomes relevant when the original specimen cannot support accurate diagnosis, characterization, or biomarker assessment. Imaging may help the team judge whether the tissue reflects the lesion, while a repeat biopsy or alternative sample can provide material better suited to the clinical question. This approach may support treatment selection and reduce delays caused by nondiagnostic results.